Mokhtari 2020

Current Status of Trial
Completed
Study Aim
Other
Study Design
RCT
Blinding
Unclear
Intervention type
Pharmacological
Intervention
Aripiprazole // Placebo
Dosage and Duration
53 patients, 18 to 80 years old, were randomized to receive enteric aripiprazole (15 mg) or placebo for up to 7 days.
Absolute Number of Participants
53
Health Status/Diagnosis
Intensive Care Unit (ICU)
Unit of Allocation and/or Setting
Hospitalised // Intensive Care Unit (ICU)
Primary outcomes
Delirium
Key Points
"Delirium incidence and the mean days to its onset were 20% vs. 55% (p = 0.022) and 2.17 +/- 0.41 vs. 2.09 +/- 0.30 (p = 0.076) in the aripiprazole and placebo groups, respectively. The mean number of delirium-free days were: 5.6 (95%CI, 4.6-6.5) and 4.3 (95%CI, 3.2-5.4), in aripiprazole and placebo groups, respectively (p = 0.111). The prevalence of delirium during the follow-up was significantly lower in the aripiprazole group (p = 0.018). Serious aripiprazole adverse reactions were not observed. Conclusion(s): Aripiprazole can reduce the incidence of delirium in the neurosurgical ICU. Studies with larger sample size in diverse ICU settings and longer follow-up are needed to confirm our findings." Mokhtari 2020